Complications of Beta Thalassemia Major
Heart failure from cardiac iron accumulation is the most common cause of death in beta thalassemia major, with other major complications including endocrine dysfunction (hypogonadism, growth hormone deficiency, diabetes), hepatic iron overload, osteoporosis, and increased infection risk. 1
Cardiac Complications (Leading Cause of Mortality)
Heart failure secondary to myocardial siderosis represents the primary mortality risk in beta thalassemia major, directly resulting from chronic transfusional iron overload 1. The cardiac complications include:
- Dilated cardiomyopathy from iron deposition in myocardium
- Arrhythmias, particularly atrial fibrillation
- Pulmonary hypertension
- Acute decompensated heart failure (medical emergency)
The risk stratification is clear: patients with cardiac T2* <6 ms have a **47% risk of developing heart failure within one year**, with a relative risk 270 times higher than those with T2* >10 ms 1. Cardiac complications affect up to 71% of beta thalassemia major patients 2, making this the dominant clinical concern.
Key Diagnostic Pitfall
Standard clinical assessment is unreliable because chronic anemia creates baseline cardiovascular adaptations that mask cardiac dysfunction: resting tachycardia, low blood pressure, enlarged end-diastolic volume, high ejection fraction, and high cardiac output 1. Background dyspnea from anemia further obscures heart failure symptoms. Serum ferritin and liver iron concentration are NOT adequate surrogates for cardiac iron measurement 1.
Endocrine Complications
Endocrine dysfunction affects 16.8% of patients with multiple systems involved 3:
Most Common Endocrinopathies (in order of frequency):
- Growth hormone deficiency (6.0%) - presenting as short stature in 65.5% of patients 3
- Diabetes mellitus (4.9%) - both insulin-dependent and non-insulin dependent forms 3
- Hypogonadism (4.5%) - manifesting as amenorrhea (16.4%) and delayed puberty (13.3%) 3
- Hypothyroidism (3.2%) 3
- Hypoparathyroidism with hypocalcemia (5.2%) 3
- Adrenal insufficiency 4
Higher serum ferritin at chelation initiation directly predicts diabetes development 5. The median age for hypogonadism development is 15.9 years, with only 50% remaining complication-free at 20 years 5.
Hepatic Complications
Liver complications develop early, with a median onset at 7.3 years and only 54% remaining complication-free at 20 years 5. These include:
- Hepatic siderosis
- Cirrhosis
- Hepatic fibrosis
Skeletal Complications
Osteoporosis develops at a median age of 20.7 years, with 96% complication-free probability at 20 years 5. Osteopenia is common in transfusion-dependent patients 4.
Infectious Complications
Beta thalassemia major causes impaired immunity, increasing susceptibility to severe infections 6. Streptococcal toxic shock syndrome, though rare, can be life-threatening and requires aggressive management with antibiotics and intravenous immunoglobulin 6.
Pain
Pain has emerged as a common complication affecting quality of life, though specific prevalence data and management strategies remain understudied 7.
Reproductive Dysfunction
Reproductive complications occur specifically in transfusion-dependent patients, related to iron-mediated gonadal damage 4.
Temporal Pattern and Risk Factors
Patients born after 1980 demonstrate significantly lower risk of death (p=0.005), hypogonadism (p<0.0001), and cardiac complications (p=0.004) 5, reflecting improvements in transfusion and chelation practices.
The number of complications directly predicts mortality (p=0.0038) 5. Delayed initiation of iron chelation has persistent negative impact even after long-term follow-up, with median chelation start at 4.8 years showing worse outcomes 5.
Critical Age Thresholds for Screening:
- Before age 10 years: Begin screening in transfusion-dependent patients 4
- From age 11 years onward: Begin screening in non-transfusion-dependent patients 4
Multiple endocrinopathies occur in 21.3% of affected patients (16.5% with two endocrine dysfunctions, 4.8% with three or more) 3, requiring comprehensive surveillance across all endocrine axes.